PremiumThe FlyViracta Therapeutics downgraded to Neutral from Buy at Rodman & Renshaw Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure Viracta Therapeutics announces exploration of strategic alternatives PremiumCompany AnnouncementsViracta Therapeutics Restructures to Focus on Nana-val Program VIRX Upcoming Earnings Report: What to Expect? Viracta Therapeutics downgraded to Market Perform from Outperform at Leerink PremiumPre-EarningsVIRX Upcoming Earnings Report: What to Expect? Xoma receives $8.1M milestone related to Day One’s sale of PRV Day One Biopharmaceuticals announces sale of Priority Review Voucher for $108M 
